Novartis AG ADR Stock
€88.60
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | 1.380% | 0.682% | -0.225% | -0.895% | -2.851% | 20.708% | 28.406% |
| Roche Holding AG ADR | 2.740% | -0.776% | -3.456% | -18.590% | -11.752% | -18.723% | - |
| Bayer AG ADR | 3.880% | -5.634% | 6.349% | -55.034% | -22.093% | -50.735% | -55.629% |
| GSK plc ADR | -0.540% | -3.646% | -5.128% | 10.119% | 10.119% | -6.329% | -16.384% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its
1 Magnificent Dividend Stock to Buy and Hold
There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time
Harvard Business Professor on Failing Well
In this podcast, Motley Fool host Deidre Woollard talks about the art of failing with Amy Edmondson, the Novartis Professor of Leadership and Management at the Harvard Business School, and author of